explore -WSS

explore

author：leisure time 2025-09-27 21:55:17 - browse：8

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Continuity nursing helped my family in our darkest PICU moments

hotspot

focus

WSS

Medical records are filled with copy

The cancer drug shortage isn’t new — and neither are the solutions

General Catalyst, Summa Health deal will turn on physician buy

How to save PrEP access — and even expand it

Duchenne breakthrough therapy leaves behind pioneering families

Hepatitis C has a cure — but many Americans still lack access to it

hotspot

explore

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

The cancer drug shortage isn’t new — and neither are the solutions

Medicare details structure of new drug price negotiation program

Bright Health sells Medicare Advantage business to Molina

Medicare proposal to cover medical devices draws a mixed reaction

Apple Vision Pro: A first look at health apps on the new VR headset

Guidelines to prevent youth baseball injuries need more muscle

What we need to know about Arena Bioworks

Psychedelics group wrestles with new pharma identity

Quicker fix for pulse oximeters urged during FDA public meeting

focus

Medical records are filled with copy

Hollywood unions extend contract negotiations for actors

Novavax promises a turnaround & Lilly roils the obesity market

What does generative AI mean for health care? We asked experts

Duchenne breakthrough therapy leaves behind pioneering families

Vertex non

Wikipedia

hotspot

focus

hotspot